Global Genetic Testing Industry, Forecast of 2025–2030
Description
This research service offers a comprehensive analysis of the global genetic testing industry (specifically, germline genetic testing, which analyzes inherited genetic variations present in an individual from birth and can be passed to offspring). The industry growth is driven by a shift towards preventive care, rising maternal ages, increasing government support for early screening, declining sequencing costs, expanding payer coverage, emerging pharmacogenomics, accelerating technology adoption, and increasing clinical integration.
It categorizes the market by application, which includes prenatal screening, newborn screening, predictive or presymptomatic testing, and Other segments (preimplantation genetic testing in IVF, forensic and identity testing, and diagnostic gene panels for complex syndromes such as epilepsy and autism). It also provides a 6-year revenue forecast and an analysis of key industry participants. Regional analyses are provided for North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America.
The report offers global perspectives on the deployment of genetic testing across multiple settings, including hospital-based laboratories (public/private hospitals, maternity clinics, OB/GYN practices), diagnostic labs (reference labs and central labs), specialty clinics (clinics focused on specific medical areas, such as neurology, cardiology, endocrinology, rare diseases), and others (consisting of IVF and fertility centers, research and academic institutes, direct-to-consumer (DTC), government and public health bodies, contract research organizations (CROs), and forensic and legal agencies involved in genomic data analytics). AI-based interpretation also plays an increasingly significant role in this ecosystem.
The study is catered from the vendor side, in which the landscape comprises companies that develop and supply DNA sequencing platforms, consumables, assay kits, reagents, software tools, and bioinformatics solutions used in the detection and interpretation of genetic variants and contribute to market revenue.
The report discusses prevalent and emerging business models, analyzes trends in market access and reimbursement for genetic testing, and offers competitive assessments and revenue-share analyses. It examines market drivers and restraints, offering insights into development trends, partnerships, and the investment landscape. The report highlights companies developing disruptive NGS and CRISPR technology.
Based on technological advancements, business models, and competitive dynamics, the report identifies growth opportunities in this space for market players and other stakeholders. The base year is 2024, and the forecast period is 2025 to 2030.
It categorizes the market by application, which includes prenatal screening, newborn screening, predictive or presymptomatic testing, and Other segments (preimplantation genetic testing in IVF, forensic and identity testing, and diagnostic gene panels for complex syndromes such as epilepsy and autism). It also provides a 6-year revenue forecast and an analysis of key industry participants. Regional analyses are provided for North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America.
The report offers global perspectives on the deployment of genetic testing across multiple settings, including hospital-based laboratories (public/private hospitals, maternity clinics, OB/GYN practices), diagnostic labs (reference labs and central labs), specialty clinics (clinics focused on specific medical areas, such as neurology, cardiology, endocrinology, rare diseases), and others (consisting of IVF and fertility centers, research and academic institutes, direct-to-consumer (DTC), government and public health bodies, contract research organizations (CROs), and forensic and legal agencies involved in genomic data analytics). AI-based interpretation also plays an increasingly significant role in this ecosystem.
The study is catered from the vendor side, in which the landscape comprises companies that develop and supply DNA sequencing platforms, consumables, assay kits, reagents, software tools, and bioinformatics solutions used in the detection and interpretation of genetic variants and contribute to market revenue.
The report discusses prevalent and emerging business models, analyzes trends in market access and reimbursement for genetic testing, and offers competitive assessments and revenue-share analyses. It examines market drivers and restraints, offering insights into development trends, partnerships, and the investment landscape. The report highlights companies developing disruptive NGS and CRISPR technology.
Based on technological advancements, business models, and competitive dynamics, the report identifies growth opportunities in this space for market players and other stakeholders. The base year is 2024, and the forecast period is 2025 to 2030.
Table of Contents
116 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
